Skip to main content
Premium Trial:

Request an Annual Quote

Solexa to Pocket $61M in Stock Placement

NEW YORK, Nov. 21 (GenomeWeb News) - Solexa will sell approximately $65 million worth of common stock and warrants to a group of institutional investors, the company said yesterday.


The company said it expects to net about $61 million from the transaction.


News of the deal comes on the heels of CEO John West's recent disclosure that the company would require additional cash to get through 2006.


Under the terms of placement, Solexa will sell 10 million shares of common stock at $6.50 per share and will issue warrants to purchase approximately 3.5 million additional shares at an exercise price of $7.50 per share, the company said.


About 3.9 million shares of common stock and approximately 1.3 million warrants will be issued in a closing expected on or about Nov. 22, with the balance of roughly 6.1 million shares and warrants to purchase approximately 2.2 million shares issuing on the same terms in a second closing subject to stockholder approval, Solexa said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.